I denne population, der er svær at behandle, gav Rasilez HCT en blodtryksreduktion (systolisk/ diastolisk) på 15, 8/ 11, 9 mmHg sammenlignet med 15, 4/ 11, 3 mmHg for irbesartan/ hydrochlorthiazid, 13, 6/ 10, 3 mmHg for amlodipin/ hydrochlorthiazid og 8, 6/ 7, 9 mmHg for hydrochlorthiazid monoterapi med samme sikkerhedsprofil som for
In this difficult-to-treat population, Rasilez HCT provided a blood pressure reduction (systolic/ diastolic) of 15.8/ 11.9 mmHg compared to 15.4/ 11.3 mmHg for